🔥🐔 BizChicken 🐔🔥
Companies Similar to Carisma Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Anixa Biosciences, Inc.
Chimeric Endocrine Receptor T-cell Technology, Anti-Viral Drug Candidates, Vaccines
Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines for oncology and infectious diseases, including novel CAR-T technologies for ovarian cancer and vaccines for breast and ovarian cancer.
Symbol: ANIX
Recent Price: $2.50
Industry: Biotechnology
CEO: Dr. Amit Kumar Ph.D.
Sector: Healthcare
Employees: 4
Address: 3150 Almaden Expressway, San Jose, CA 95118
Phone: 408 708 9808
Last updated: 2024-12-31
CARGO Therapeutics, Inc. Common Stock
CRG-022
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.
About | Leadership | Directors | About | Contact | Contact | Careers | Careers | Careers | Careers | About | About
Symbol: CRGX
Recent Price: $13.76
Industry: Biotechnology
CEO: Ms. Gina Chapman
Sector: Healthcare
Employees: 150
Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403
Phone: 650-379-6143
Leadership
- Gina Chapman, President and Chief Executive Officer
- Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
- Ginna Laport, MD, Chief Medical Officer
- Shishir Gadam, PhD, Chief Technical Officer
- Michael Ports, PhD, Chief Scientific Officer
- Kari Leetch, Chief People Officer
- Halley Gilbert, JD, Chief Legal Officer
- Bethany Rogers, SVP, Product Strategy and Commercialization
- Faisal Shawwa, SVP, Finance
- Tonia J. Buchholz, PhD, Head of Clinical Science
- Kanika Chawla, PhD, Head of Process Sciences
- Sandra Chen, Head of Clinical Quality and Risk Management
- Michelle Gray, Head of Clinical Operations
- Adam Haskett, Head of External Manufacturing
- David Hoffman, JD, Head of Intellectual Property & Transactions
- Anissa Irwin, Head of Quality Assurance and Systems
- Brett Masterson, Head of Marketing
- Rob McCombie, Head of CMC Regulatory
- Frank McDonald, Head of Clinical Data Management
- Priya Parameswaran, Head of Corporate Strategy and Business Operations
- Shabnum Patel, PHD, Head of MSAT
- Mary Rodley, Head of CMC Strategy and Operations
- Abhijeet Sarvaiya, Head of Statistical Programming
- Brian Schoelkopf, Head of FP&A
- Christophe Suchet, Head of IT
- Beth Vasievich, PhD, Head of Commercial Planning and Operations
- Jun Wang, Head of Procurement
- John Orwin, Chairman of the Board
- Abraham Bassan, Board Director
- Kapil Dhingra, M.B.B.S, Board Director
- Reid Huber, PHD, Board Director
- David Lubner, Board Director
- Krishnan Viswanadhan, Pharm.D, Board Director
- Jane Pritchett Henderson, Board Director
Last updated: 2024-12-31
CERo Therapeutics Holdings, Inc.
Engineered T Cell Therapeutics
CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment, particularly targeting hematologic malignancies using innovative immune system integration strategies.
Symbol: CERO
Recent Price: $0.06
Industry: Biotechnology
CEO: Mr. Christopher B. Ehrlich M.B.A.
Sector: Healthcare
Employees: 8
Address: 201 Haskins Way, South San Francisco, CA 94080
Phone: 650-407-2376
Last updated: 2024-12-31
ImmunityBio, Inc.
Therapies and Vaccines
Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.
Symbol: IBRX
Recent Price: $2.68
Industry: Biotechnology
CEO: Mr. Richard Gerald Adcock
Sector: Healthcare
Employees: 622
Address: 3530 John Hopkins Court, San Diego, CA 92121
Phone: 858 633 0300
Last updated: 2024-12-31
Mustang Bio, Inc.
Gene and CAR T Cell Therapies
Mustang Bio, Inc. is a biopharmaceutical company specializing in cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. It focuses on developing gene therapy programs and CAR T cell therapies, including treatments for X-linked severe combined immunodeficiency and various types of cancer.
About | Leadership | Directors | News | Contact | About | About | Careers | About | About | Careers | About | About
Symbol: MBIO
Recent Price: $0.19
Industry: Biotechnology
CEO: Dr. Manuel Litchman M.D.
Sector: Healthcare
Employees: 80
Address: 377 Plantation Street, Worcester, MA 01605
Phone: 781 652 4500
Leadership
- Manuel Litchman, M.D., President, Chief Executive Officer and Director
- Greg Furrow, M.S., FRQA, Chief Quality Officer
- James Murphy, B.A., Ad interim Chief Financial Officer
- Michael S. Weiss, Chairman of the Board of Directors
- Lindsay A. Rosenwald, M.D., Director
- Adam J. Chill, Director
- Neil Herskowitz, Director
- Michael J. Zelefsky, M.D., Director
- Mustang Bio, Inc., Company
Last updated: 2024-12-31
Kiromic BioPharma, Inc.
ALEXIS-ISO-1, ALEXIS-PRO-1
Kiromic Bio Pharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company that develops multi-indication T cell therapies, leveraging the Gamma Delta T cell to target solid tumors. Key products include ALEXIS-ISO-1 and ALEXIS-PRO-1.
Symbol: KRBP
Recent Price: $0.93
Industry: Biotechnology
CEO: Mr. Pietro Bersani CPA, J.D.
Sector: Healthcare
Employees: 35
Address: 7707 Fannin, Houston, TX 77054
Phone: 832 968 4888
Leadership
- Pietro Bersani, CPA, Director
- Leonardo Mirandola, PhD, Chief Scientific Officer/Interim COO
- Scott Dahlbeck, MD, PharmD, Chief of Staff
- Brian Hungerford, Chief Financial Officer
- Michael Nagel, Chairperson
- Michael Catlin, Independent Director
- Pam Misajon, Independent Director
Last updated: 2024-12-31
Arcellx, Inc.
CART-dd BCMA
Arcellx, Inc. is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer and other incurable diseases, with a focus on its lead product candidate, CART-dd BCMA, for treating relapsed or refractory multiple myeloma.
About | About | News | Contact | Contact | Culture | Culture | Culture | Culture | About | About | About | About | About | News
Symbol: ACLX
Recent Price: $78.35
Industry: Biotechnology
CEO: Mr. Rami Elghandour
Sector: Healthcare
Employees: 130
Address: 25 West Watkins Mill Road, Gaithersburg, MD 20878
Phone: 240 327 0603
Last updated: 2024-12-31
Agenus Inc.
Retrocyte Display
Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.
Symbol: AGEN
Recent Price: $2.69
Industry: Biotechnology
CEO: Dr. Garo H. Armen Ph.D.
Sector: Healthcare
Employees: 389
Address: 3 Forbes Road, Lexington, MA 02421-7305
Phone: 781 674 4400
Last updated: 2024-12-31
Allogene Therapeutics, Inc.
UCART19
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
About | About | About | Contact | Contact | Careers | Careers | Jobs | About | About | About | About | About | About
Symbol: ALLO
Recent Price: $2.10
Industry: Biotechnology
CEO: Dr. David D. Chang M.D., Ph.D.
Sector: Healthcare
Employees: 232
Address: 210 East Grand Avenue, South San Francisco, CA 94080
Phone: 650 457 2700
Last updated: 2024-12-31
Atara Biotherapeutics, Inc.
T-cell immunotherapy treatments
Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.
About | About | About | Contact | About | Careers | Careers | About | Careers | Careers | About | About
Symbol: ATRA
Recent Price: $13.28
Industry: Biotechnology
CEO: Dr. Anhco Nguyen Ph.D.
Sector: Healthcare
Employees: 165
Address: 611 Gateway Boulevard, South San Francisco, CA 94080
Phone: 650 278 8930
Last updated: 2024-12-31
Cabaletta Bio, Inc.
DSG3-CAART
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its leading product, DSG3-CAART, is in Phase I trials for treating mucosal pemphigus vulgaris.
Symbol: CABA
Recent Price: $2.24
Industry: Biotechnology
CEO: Dr. Steven A. Nichtberger M.D.
Sector: Healthcare
Employees: 136
Address: 2929 Arch Street, Philadelphia, PA 19104
Phone: 267 759 3100
Leadership
- Steven Nichtberger, M.D., President, Chief Executive Officer, and Co-Founder
- Samik Basu, M.D., Chief Scientific Officer
- Gwendolyn Binder, Ph.D., President, Science & Technology
- David J. Chang, M.D., M.P.H, FACR, Chief Medical Officer
- Arun Das, M.D., Chief Business Officer
- Michael Gerard, General Counsel
- Heather Harte-Hall, Chief Compliance Officer
- Anup Marda, Chief Financial Officer
- Martha O’Connor, Chief Human Resources Officer
- Sarah Yuan, Ph.D., Chief Technology Officer
- Catherine Bollard, M.D., Independent Director, George Washington University
- Scott Brun, M.D., Independent Director, formerly at AbbVie
- Richard Henriques, M.B.A., Independent Director, former CFO of Gates Foundation, former Controller at Merck
- Mark Simon, M.B.A., Independent Director, Torreya Partners
- Shawn Tomasello, M.B.A., Independent Director, former CCO of Kite Pharma, Inc.
Last updated: 2024-12-31
Carisma Therapeutics, Inc.
chimeric antigen receptors (CAR) macrophages
Carisma Therapeutics, Inc. is a biopharmaceutical company that develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors, leveraging advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy.
Symbol: CARM
Recent Price: $0.44
Industry: Biotechnology
CEO: Mr. Steven Kelly
Sector: Healthcare
Employees: 107
Address: 3675 Market St., Philadelphia, PA 19104
Phone: 484 899 0326
Leadership
- Steven Kelly, President & CEO
- Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer
- Eugene Kennedy, MD, Chief Medical Officer
- Kenneth Locke, Senior Vice President, Technical Operations
- Richard Morris, Chief Financial Officer
- Terry Shields, Senior Vice President, Human Resources
- Eric Siegel, General Counsel and Corporate Secretary
- Tom Wilton, Chief Business Officer
- Sascha Abramson, PhD, Vice President, Scientific Operations
- Heather Ansorge, PhD, VP, Program and Portfolio Management
- Thomas Condamine, PhD, Vice President, Discovery and Translational Sciences
Last updated: 2024-12-31
Celularity Inc.
CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.
About | Leadership | Directors | About | About | About | About | Directors | Careers | About | About | About | About | About | About
Symbol: CELU
Recent Price: $2.05
Industry: Biotechnology
CEO: Dr. Robert Joseph Hariri M.D., Ph.D.
Sector: Healthcare
Employees: 120
Address: 170 Park Avenue, Florham Park, NJ 07932
Phone: 908 768 2170
Leadership
- Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
- David Beers, CFA, Chief Financial Officer
- Stephen Brigido, DPM, President, Degenerative Diseases
- John Haines, Global Manager and Chief Administrative Officer
- K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
- John Colerangle, DVM, Ph.D., Regulatory Affairs
- Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
- Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
- Carmine Palummo, Corporate Operations
- Tim Wilk, Technical Operations
- Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
- Peter Diamandis, M.D., Director
- Dean Kehler, Director
- Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
- Diane Parks, Director
Last updated: 2024-12-31
Celldex Therapeutics, Inc.
therapeutic monoclonal and bispecific antibodies
Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and cancers.
About | About | Management | Directors | About | Contact | About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About
Symbol: CLDX
Recent Price: $25.12
Industry: Biotechnology
CEO: Mr. Anthony S. Marucci M.B.A.
Sector: Healthcare
Employees: 160
Address: Perryville III Building, Hampton, NJ 08827
Phone: 908 200 7500
Leadership
- Anthony S. Marucci, Founder, President, Chief Executive Officer and Director
- Tibor Keler, Ph.D., Founder, Executive Vice President and Chief Scientific Officer
- Diane C. Young, M.D., Senior Vice President and Chief Medical Officer
- Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
- Sam Martin, Senior Vice President and Chief Financial Officer
- Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer
- Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer
- Sarah Cavanaugh, Senior Vice President, Corporate Affairs and Administration
- Margo Heath-Chiozzi, M.D., Senior Vice President, Regulatory Affairs
- Freddy A. Jimenez, Esq., Senior Vice President and General Counsel
- Karen L. Shoos, J.D., Former Chair, Director of Operations, Maryland Tech Council Venture Mentoring Services Program
- Keith L. Brownlie, Former Partner, Ernst & Young LLP
- Herbert J. Conrad, Former President, Roche Pharmaceuticals US
- James J. Marino, J.D., Former Partner, Dechert LLP
- Harry H. Penner, Jr., J.D., L.L.M., Former Chairman and CEO, Nascent Bioscience
- Cheryl L. Cohen, President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
- Dr. Garry Neil, Chief Executive Officer; Chair of the Board, Avalo Therapeutics
- Rita Jain, M.D., Former Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc.
- Carl June, M.D.,
- Michel Nussenzweig, M.D., Ph.D.,
- Marc E. Rothenberg M.D., Ph.D.,
- Joseph Schlessinger, Ph.D.,
- Louis Weiner, M.D.,
Last updated: 2024-12-31
Caribou Biosciences, Inc.
CB-010, CB-011, CB-012, CB-020
Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.
About | About | Contact | Contact | Careers | Jobs | Benefits | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Careers | About | About | Vision/Values | DEI | Benefits
Symbol: CRBU
Recent Price: $1.61
Industry: Biotechnology
CEO: Dr. Rachel E. Haurwitz Ph.D.
Sector: Healthcare
Employees: 158
Address: 2929 7th Street, Berkeley, CA 94710
Phone: 510 982 6030
Last updated: 2024-12-31
Precision BioSciences, Inc.
ARCUS
Precision Bio Sciences, Inc. is a clinical stage gene editing company specializing in in vivo gene editing and ex vivo allogeneic CAR T therapies, including the ARCUS genome editing platform and various investigational CAR T immunotherapies.
Contact | Careers | Careers | Careers | Careers | Leadership | Leadership | Leadership | Careers | Careers | About | About | About
Symbol: DTIL
Recent Price: $4.26
Industry: Biotechnology
CEO: Mr. Michael Amoroso
Sector: Healthcare
Employees: 109
Address: 302 East Pettigrew Street, Durham, NC 27701
Phone: 919 314 5512
Last updated: 2024-12-31
Nkarta, Inc.
NKX101 and NKX019
Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.
About | Contact | Careers | Careers | Careers | Jobs | Careers | Careers | Careers | Careers | Careers | Careers | Contact | Careers | About | Careers
Symbol: NKTX
Recent Price: $2.32
Industry: Biotechnology
CEO: Mr. Paul J. Hastings
Sector: Healthcare
Employees: 150
Address: 6000 Shoreline Court, South San Francisco, CA 94080
Phone: 415 582 4923
Last updated: 2024-12-31
Poseida Therapeutics, Inc.
P-PSMA-101
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on developing innovative CAR-T therapies for patients with high unmet medical needs, including treatments for prostate cancer, multiple myeloma, and various solid tumors.
Symbol: PSTX
Recent Price: $9.48
Industry: Biotechnology
CEO: Dr. Kristin Yarema Ph.D.
Sector: Healthcare
Employees: 337
Address: 9390 Towne Centre Drive, San Diego, CA 92121
Phone: 858 779 3100
Last updated: 2024-12-31
TScan Therapeutics, Inc.
T cell receptor-engineered T cell therapies
TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company that develops T cell receptor-engineered T cell therapies for cancer treatment. It is working on therapies for hematologic malignancies and solid tumors, as well as vaccines for infectious diseases like SARS-CoV-2.
About | About | Management | Directors | About | About | Contact | Careers | Careers | Careers | About | About
Symbol: TCRX
Recent Price: $3.00
Industry: Biotechnology
CEO: Dr. Gavin MacBeath Ph.D.
Sector: Healthcare
Employees: 175
Address: 830 Winter Street, Waltham, MA 02451
Phone: 857 399 9500
Leadership
- Stephen Biggar, M.D., Ph.D., Partner at Baker Bros. Advisors LP
- Katina Dorton, J.D., M.B.A., CFO of Nodthera
- Gabriela Gruia, M.D., Chief Development Officer at Ichnos Sciences
- Barbara Klencke, M.D., Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.
- Gavin MacBeath, Ph.D., CEO of TSCAN
- Garry Nicholson, Former President of Pfizer Oncology
- R. Keith Woods, Former Chief Operating Officer of argenx
Last updated: 2024-12-31
Xenetic Biosciences, Inc.
XCART
Xenetic Biosciences, Inc. is a biopharmaceutical company that focuses on advancing XCART, a personalized CAR T platform technology for oncology therapeutics and biologic drug development.
About | Leadership | Directors | About | About | About | Contact | Careers | About | About | About
Symbol: XBIO
Recent Price: $4.05
Industry: Biotechnology
CEO: Mr. James F. Parslow
Sector: Healthcare
Employees: 4
Address: 40 Speen Street, Framingham, MA 01701
Phone: 781 778 7720
Leadership
- James F. Parslow, Interim Chief Executive Officer and Chief Financial Officer
- Scott N. Cullison, Business Development
- Reid P. Bissonnette, Ph.D., Translational Research and Development
- Cory C. Kauffman, Ph.D., Chief Technology Officer
- Adam Logal, Chairman
- Grigory G. Borisenko, Ph.D., Non-Executive Director
- James Eric Callaway, Ph.D., Non-Executive Director
- Firdaus Jal Dastoor, FCS, Non-Executive Director
- Dmitry Genkin, MD, Non-Executive Director
- Roger Kornberg, Ph.D., Non-Executive Director
- Moshe Mizrahy, Non-Executive Director
- Dr. Alexey Vinogradov, Non-Executive Director
Last updated: 2024-12-31